This segment focuses on enabling and accelerating the discovery and development of biotherapeutics using Berkeley Lights' digital cell biology platform. The platform integrates proprietary consumables, automation systems, and application software to streamline workflows for antibody discovery, cell line development, and synthetic biology applications. Research and development activities include optimizing the OptoSelect chips and reagent kits, enhancing automation capabilities, and expanding the software functionalities to support diverse cell-based assays. The segment aims to improve the speed and efficiency of biotherapeutic development, reducing time-to-market and enabling the creation of novel therapies for various diseases. Collaborations with pharmaceutical companies and research institutions are crucial for validating the platform's capabilities and expanding its applications in drug discovery.

This segment is dedicated to the development of stable and high-producing cell lines for biopharmaceutical manufacturing. Berkeley Lights' platform enables rapid screening and selection of cells with desired characteristics, such as high productivity, stability, and product quality. Research and development efforts focus on improving the efficiency of cell line engineering, optimizing culture conditions, and developing advanced selection methods. The platform's ability to manipulate and analyze single cells allows for the identification of rare clones with superior performance. This segment aims to reduce the time and cost associated with cell line development, enabling faster production of biotherapeutics and other cell-based products. Collaborations with biopharmaceutical companies are essential for validating the platform's performance and expanding its adoption in manufacturing processes.